Royalty Report: Drugs, Therapeutic, Gastrointestinal – Collection: 210017

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Therapeutic
  • Gastrointestinal
  • HIV / AIDs
  • Disease

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 210017

License Grant
The Licensor entered into a license agreement with the China Licensee for the development of crofelemer for the indications of HIV/AIDS diarrhea, pediatric diarrhea and adult acute infectious diarrhea.
License Property
The Licensor focuses on the development and commercialization of proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.
Field of Use
The China Licensee will strive to develop crofelemer for any indications in its licensed territory.

IPSCIO Record ID: 189370

License Grant
Licensee entered into a royalty agreement with Licensor whereby it agreed to pay Licensor royalties on crofelemer in western territories. This agreement was to remain in effect until such time as Licensee is no longer receiving royalties from the sale of crofelemer products in western territories.
License Property
Crofelemer is an active pharmaceutical ingredient in Mytesi which is a human drug for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 197787

License Grant
The agreement is for products containing crofelemer or any derivative thereof obtained from any species of the Croton lechleri plant.
License Property
The product is defined as all products for the treatment, maintenance or improvement of human health which are prescription medicines, botanicals, dietary supplements sold for the treatment of diarrhea, Irritable Bowel Syndrome (IBS) or herpes.
Field of Use
This agreement is for the pharmaceutical industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.